Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients

Meinolf Suttorp, Markus Metzler, Frederic Millot, Hiroyuki Shimada, Deepak Bansal, Adalet Meral Günes, Krzysztof Kalwak, Petr Sedlacek, Andre Baruchel, Andrea Biondi, Nobuko Hijiya, Kirk R. Schultz, Martin Schrappe

研究成果: Article

2 引用 (Scopus)

抄録

Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

元の言語English
ジャーナルPediatric Blood and Cancer
DOI
出版物ステータスAccepted/In press - 2018 1 1

Fingerprint

Leukemia
Pediatrics
Therapeutics
Imatinib Mesylate
Economics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

これを引用

Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients. / Suttorp, Meinolf; Metzler, Markus; Millot, Frederic; Shimada, Hiroyuki; Bansal, Deepak; Günes, Adalet Meral; Kalwak, Krzysztof; Sedlacek, Petr; Baruchel, Andre; Biondi, Andrea; Hijiya, Nobuko; Schultz, Kirk R.; Schrappe, Martin.

:: Pediatric Blood and Cancer, 01.01.2018.

研究成果: Article

Suttorp, M, Metzler, M, Millot, F, Shimada, H, Bansal, D, Günes, AM, Kalwak, K, Sedlacek, P, Baruchel, A, Biondi, A, Hijiya, N, Schultz, KR & Schrappe, M 2018, 'Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients', Pediatric Blood and Cancer. https://doi.org/10.1002/pbc.27431
Suttorp, Meinolf ; Metzler, Markus ; Millot, Frederic ; Shimada, Hiroyuki ; Bansal, Deepak ; Günes, Adalet Meral ; Kalwak, Krzysztof ; Sedlacek, Petr ; Baruchel, Andre ; Biondi, Andrea ; Hijiya, Nobuko ; Schultz, Kirk R. ; Schrappe, Martin. / Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients. :: Pediatric Blood and Cancer. 2018.
@article{07c5d755a66a4801a3d96bb73dd16a35,
title = "Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients",
abstract = "Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.",
keywords = "generic medication, imatinib inhibitor, pediatric, Ph+ leukemia, tyrosine kinase",
author = "Meinolf Suttorp and Markus Metzler and Frederic Millot and Hiroyuki Shimada and Deepak Bansal and G{\"u}nes, {Adalet Meral} and Krzysztof Kalwak and Petr Sedlacek and Andre Baruchel and Andrea Biondi and Nobuko Hijiya and Schultz, {Kirk R.} and Martin Schrappe",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/pbc.27431",
language = "English",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients

AU - Suttorp, Meinolf

AU - Metzler, Markus

AU - Millot, Frederic

AU - Shimada, Hiroyuki

AU - Bansal, Deepak

AU - Günes, Adalet Meral

AU - Kalwak, Krzysztof

AU - Sedlacek, Petr

AU - Baruchel, Andre

AU - Biondi, Andrea

AU - Hijiya, Nobuko

AU - Schultz, Kirk R.

AU - Schrappe, Martin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

AB - Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

KW - generic medication

KW - imatinib inhibitor

KW - pediatric

KW - Ph+ leukemia

KW - tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=85052796606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052796606&partnerID=8YFLogxK

U2 - 10.1002/pbc.27431

DO - 10.1002/pbc.27431

M3 - Article

C2 - 30160364

AN - SCOPUS:85052796606

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -